Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Net Income towards Common Stockholders: 2022-2023

Historic Net Income towards Common Stockholders for Lexeo Therapeutics (LXEO) over the last 1 years, with Dec 2023 value amounting to -$14.2 million.

  • Lexeo Therapeutics' Net Income towards Common Stockholders rose 2.68% to -$14.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$66.4 million, marking a year-over-year change of. This contributed to the annual value of -$98.3 million for FY2024, which is 48.11% down from last year.
  • As of Q4 2023, Lexeo Therapeutics' Net Income towards Common Stockholders stood at -$14.2 million, which was up 29.45% from -$20.1 million recorded in Q3 2023.
  • Over the past 5 years, Lexeo Therapeutics' Net Income towards Common Stockholders peaked at -$13.4 million during Q2 2023, and registered a low of -$20.1 million during Q3 2023.
  • Its 2-year average for Net Income towards Common Stockholders is -$16.3 million, with a median of -$15.8 million in 2022.
  • Within the past 5 years, the most significant YoY rise in Lexeo Therapeutics' Net Income towards Common Stockholders was 2.68% (2023), while the steepest drop was 17.90% (2023).
  • Lexeo Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$14.6 million in 2022, then grew by 2.68% to -$14.2 million in 2023.
  • Its Net Income towards Common Stockholders stands at -$14.2 million for Q4 2023, versus -$20.1 million for Q3 2023 and -$13.4 million for Q2 2023.